{"title":"治疗学和肿瘤学PET的最新进展：新出现的放射性核素和靶标。","authors":"Tadashi Watabe, Kenji Hirata, Mami Iima, Masahiro Yanagawa, Tsukasa Saida, Akihiko Sakata, Satoru Ide, Maya Honda, Ryo Kurokawa, Kentaro Nishioka, Mariko Kawamura, Rintaro Ito, Koji Takumi, Seitaro Oda, Shunsuke Sugawara, Keitaro Sofue, Daiju Ueda, Shinji Naganawa","doi":"10.1007/s12149-025-02090-z","DOIUrl":null,"url":null,"abstract":"<div><p>Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (<sup>161</sup>Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to <sup>177</sup>Lu. Alpha emitters, such as astatine (<sup>211</sup>At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [<sup>211</sup>At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 9","pages":"909 - 921"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-025-02090-z.pdf","citationCount":"0","resultStr":"{\"title\":\"Recent advances in theranostics and oncology PET: emerging radionuclides and targets\",\"authors\":\"Tadashi Watabe, Kenji Hirata, Mami Iima, Masahiro Yanagawa, Tsukasa Saida, Akihiko Sakata, Satoru Ide, Maya Honda, Ryo Kurokawa, Kentaro Nishioka, Mariko Kawamura, Rintaro Ito, Koji Takumi, Seitaro Oda, Shunsuke Sugawara, Keitaro Sofue, Daiju Ueda, Shinji Naganawa\",\"doi\":\"10.1007/s12149-025-02090-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (<sup>161</sup>Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to <sup>177</sup>Lu. Alpha emitters, such as astatine (<sup>211</sup>At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [<sup>211</sup>At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.</p></div>\",\"PeriodicalId\":8007,\"journal\":{\"name\":\"Annals of Nuclear Medicine\",\"volume\":\"39 9\",\"pages\":\"909 - 921\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-07-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s12149-025-02090-z.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12149-025-02090-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-025-02090-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Recent advances in theranostics and oncology PET: emerging radionuclides and targets
Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (161Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to 177Lu. Alpha emitters, such as astatine (211At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [211At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.
期刊介绍：
Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine.
The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
